HealthRX

A telehealth service selling compounded semaglutide and tirzepatide across a large programmatic library. It publishes no legal entity and no street address.

Passes 5 of 8 criteria. Recorded against Standard v1.1, August 2026.

Operating entity Footer, contact, terms and privacy were read, and no legal entity name appears on any of them.

Dispositions at a glance

Code	Criterion	Disposition
S1	Prescriber requirement	PASS
S2	Prescription gating	PASS
S3	Pharmacy identification	FAIL
S4	Compounding disclosure	PASS
S5	Analytical documentation	FAIL
S6	Business address	FAIL
S7	Price disclosure	PASS
S8	Enforcement status	PASS

Evidence, criterion by criterion

What was read, where, and on what date, for each disposition in the table above.

S1PASSAn independent United States board-certified physician reviews the file within 24 hours and writes a prescription if clinically appropriate.Source: healthrx.com · read August 2026.

S2PASSThe order path was walked from the offer page and stopped at the first intake question about the buyer's goal.Source: healthrx.com/glp1-offer-v1/intake/height-weight · read August 2026.

S3FAILFulfillment is attributed to a licensed 503A pharmacy on the home page and in the footer, and no pharmacy is named.Source: healthrx.com · read August 2026.

S4PASSCompounded medications are not reviewed or approved by the FDA, stated under the product cards on the home page.Source: healthrx.com · read August 2026.

S5FAILMedication is described as lot-tracked from the compounding bench to the door, and no lot document is reachable.Source: healthrx.com · read August 2026.

S6FAILFooter, contact, terms and privacy carry no entity and no address, only a copyright line, an email address and a telephone number.Source: healthrx.com/contact-us, healthrx.com/terms, healthrx.com/privacy · read August 2026.

S7PASSCompounded semaglutide from 133 dollars per month on a three-month plan, and 99 dollars per month on a twelve-month plan.Source: healthrx.com · read August 2026.

S8PASSNo letter names the entity in the FDA index, and no action has halted the business; control letter found in the same run.Source: FDA warning-letter index · read August 2026.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, sexual health medications, hair loss medications, NAD+, sermorelin.

Dispositions recorded against Standard v1.1, August 2026. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.